Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted Therapy for Adjustment Disorder in Cancer Patients and Significant Others
NCT05584826Phase 2Recruiting
- Sponsor
- Sunstone Therapies
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in adjustment disorder (AD), sponsored by Sunstone Therapies. Primary endpoint: Effectiveness of the intervention on Adjustment Disorder and relationship functioning at 8 weeks. Started Oct 2022; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
adjustment disorder (AD)
Beyond the preview
Go deeper on NCT05584826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584826.